Related Experiment Video
Updated: Dec 6, 2025

Real-time Observation of the DNA Strand Exchange Reaction Mediated by Rad51
Published on: February 13, 2019
Regulation and pharmacological targeting of RAD51 in cancer
McKenzie K Grundy1, Ronald J Buckanovich2,3, Kara A Bernstein1
1Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Abstract:
Regulation of homologous recombination (HR) is central for cancer prevention. However, too little HR can increase cancer incidence, whereas too much HR can drive cancer resistance to therapy. Importantly, therapeutics targeting HR deficiency have demonstrated a profound efficacy in the clinic improving patient outcomes, particularly for breast and ovarian cancer. RAD51 is central to DNA damage repair in the HR pathway. As such, understanding the function and regulation of RAD51 is essential for cancer biology. This review will focus on the role of RAD51 in cancer and beyond and how modulation of its function can be exploited as a cancer therapeutic.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
DNA Damage can Stall the Cell Cycle
Restarting Stalled Replication Forks
Negative Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

